Get the Stockscreener App
4.71
8.19%
-0.42
After Hours:
4.76
0.05
+1.06%
Sagimet Biosciences Inc stock is traded at $4.71, with a volume of 734.96K.
It is down -8.19% in the last 24 hours and down -30.53% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
See More
Previous Close:
$5.13
Open:
$5.14
24h Volume:
734.96K
Relative Volume:
0.78
Market Cap:
$151.64M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-3.9713
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+16.01%
1M Performance:
-30.53%
6M Performance:
+66.43%
1Y Performance:
-25.83%
1-Day Range:
$4.6305
$5.20
1-Week Range:
$4.0574
$5.2199
52-Week Range:
$2.39
$8.75
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
4.71 | 151.64M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Prepare Yourself for Liftoff: Sagimet Biosciences Inc (SGMT) - SETE News
Sagimet Biosciences Inc (SGMT)’s results reveal risk - US Post News
Analytical Overview: Sagimet Biosciences Inc (SGMT)’s Ratios Tell a Financial Story - The Dwinnex
Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity - TipRanks
What's Going On With Sagimet Biosciences Stock On Thursday? - MSN
JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate - MSN
Barclays PLC Has $159,000 Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
With 43% stake, Sagimet Biosciences Inc. (NASDAQ:SGMT) seems to have captured institutional investors' interest - Simply Wall St
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com
Geode Capital Management LLC Acquires 91,246 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
When (SGMT) Moves Investors should Listen - Stock Traders Daily
Gaining Ground: Sagimet Biosciences Inc (SGMT) Closes Lower at 5.37, Down -3.59 - The Dwinnex
Barclays PLC Boosts Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - The Manila Times
Sagimet to Present Breakthrough MASH Treatment Data at MASH-TAG Conference 2025 - StockTitan
Sagimet Biosciences Updates Investor Presentation in Recent 8-K Filing - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Average PT from Analysts - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
(SGMT) Trading Advice - Stock Traders Daily
Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress
Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
(SGMT) On The My Stocks Page - Stock Traders Daily
Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Oppenheimer - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited (NASDAQ:SGMT) - Seeking Alpha
Oppenheimer sets $30 target on Sagimet Biosciences shares - Investing.com
How To Trade (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):